STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2236 by analyst upside · 2026-06-29
TEVA
Teva Pharmaceutical Industries Limited
Healthcare · Market Cap $39B · P/E 24.8x
ANALYST PRICE TARGET
+23.2%
implied upside to consensus target
Current Price $33.21
Consensus Target $40.9
Bull Target $50.0
Bear Target $33.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
1
Sell
0
52-Week Low $14.99
52-Week High $37.35
YTD Return +7.3%
FUNDAMENTALS
Market Cap $39B
P/E Ratio (TTM) 24.8x
Forward P/E 10.8x
EPS (TTM) $1.34
PEG Ratio 0.95
Dividend Yield N/A
Revenue (TTM) $17.3B
Profit Margin 9.0%
52-WEEK RANGE
52-Week Low $14.99
52-Week High $37.35
Current Price $33.21
Bear Target $33.0
Bull Target $50.0
● Now $33.21 ● Target $40.9
TRADING DATA
Avg Volume 6.2M
YTD Return +7.3%
Analyst Count 10
Consensus Buy
Upside to Target +23.2%
Last Updated 2026-06-29

ANALYST SUMMARY

Teva Pharmaceutical Industries Limited (TEVA) is currently trading at $33.21 with a Wall Street consensus price target of $40.9, implying potential upside of 23.2% over the next 12 months. 10 analysts currently cover TEVA, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $33.0.

TEVA operates in the Healthcare sector with a market capitalisation of $39B. The stock is up 7.3% year-to-date and is currently trading near the upper end of its 52-week range of $14.99 – $37.35.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TEVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays — Reiterated
Overweight → Overweight 2026-05-06 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-04-30 43% win rate (7 calls)
UBS — Reiterated
Buy → Buy 2026-04-30 33% win rate (6 calls)
Piper Sandler reit
Overweight → Overweight 2026-04-30 14% win rate (7 calls)
Truist Securities — Reiterated
Buy → Buy 2026-04-30 Building track record
B of A Securities — Reiterated
Buy → Buy 2026-04-09 Building track record
Piper Sandler reit
Overweight → Overweight 2026-03-04 14% win rate (7 calls)
Truist Securities — Reiterated
Buy → Buy 2026-02-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
60
out of 100
Coverage depth
18/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →